Education
About Us
Working with TipRanks
Follow Us
Ondine Biomedical, Inc. (GB:OBI)
:OBI
OBI Stock Chart & Stats
Day’s Range― - ―
52-Week Range5.00p - 13.30p
Previous CloseN/A
Volume7.12K
Average Volume (3M)191.60K
Market Cap
£41.00M
Enterprise Value18.12M
Total Cash (Recent Filing)C$13.13M
Total Debt (Recent Filing)C$896.00K
Price to Earnings (P/E)―
Beta0.57
Next Earnings
May 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding443,233,200
10 Day Avg. Volume144,271
30 Day Avg. Volume191,597
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)51.81
Price to Cash Flow (P/CF)-6.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
55.00pPrice Target Upside494.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Ondine Biomedical, Inc. News
PremiumCompany Announcements
Ondine Biomedical Announces Board Change with Mike Farrar’s Resignation
PremiumCompany Announcements
Ondine Biomedical Launches ICU Pilot Study for Steriwave Technology
PremiumCompany Announcements
Ondine Biomedical Launches ICU Pilot Study for Steriwave Technology
PremiumCompany Announcements
Ondine Biomedical’s Steriwave Therapy Reduces Spine Surgery Infections
PremiumCompany Announcements
Ondine Biomedical Expands Share Capital with New Option Exercise
PremiumCompany Announcements
Ondine Biomedical Strengthens Leadership with Stock Option Grants
---
Options Prices
Currently, No data available
---
Ownership Overview
40.73% Insiders
―
Mutual Funds
― Other Institutional Investors
59.27% Public Companies and
Individual Investors
OBI FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest share price was 5.00p and its highest was 13.30p in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is £41.00M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is May 15, 2025 which is in 40 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Sep 30, 2024. The company reported -0.019p earnings per share for the quarter, missing the consensus estimate of N/A by -0.019p.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Undervalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 443,233,200 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -0.019p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in GB:OBI
---
Ondine Biomedical, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
55.00p (494.59% Upside)
55.00p (494.59% Upside)
Insider Transactions
Bought Shares
Worth £58.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.93%
12-Months-Change
Fundamentals
Return on Equity
-675.80%
Trailing 12-Months
Asset Growth
-47.14%
Trailing 12-Months
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
---
OBI Stock 12 Month Forecast
Average Price Target
55.00p
▲(494.59% Upside)
Technical Analysis
Best Analysts Covering OBI
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+3.60%
reiterated a buy rating last month
Copying Jack Reynolds-Clark's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.60% per trade.
---